Skip to main content

Table 1 Patient and clinicopathologic characteristics

From: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma

Characteristic

HTP group

(n = 29)

TTP group

(n = 20)

TACE alone group

(n = 34)

p-value

Sex

   

0.6261

 Male

27 (93.10)

17 (85.00)

31 (91.18)

 

 Female

2 (6.90)

3 (15.00)

3 (8.82)

 

Age (years)

   

0.7676

 Mean (SD)

54.48 (10.43)

56.05 (11.68)

56.41 (10.69)

 

Hepatitis B surface antigen

   

0.8248

 Positive

25 (86.21)

16 (80.00)

29 (85.29)

 

 Negative

4 (13.79)

4 (20.00)

5 (14.71)

 

Liver cirrhosis

   

0.5544

 Yes

19 (65.52)

10 (50.00)

20 (58.82)

 

 No

10 (34.48)

10 (50.00)

14 (41.18)

 

AFP (ng/mL)

   

0.9183

 < 400

23 (79.31)

15 (75.00)

27 (79.41)

 

 ≥ 400

6 (20.69)

5 (25.00)

7 (20.59)

 

ALT (U/L)

   

0.4888

 Median (IQR)

25.60 (33)

28.50 (24)

25.65 (17)

 

AST (U/L)

   

0.3848

 Median (IQR)

34.60 (29)

32.60 (19)

27.55(16)

 

GGT (U/L)

   

0.1051

 Median (IQR)

112.60 (135.85)

88.74 (89.70)

57.44 (70.00)

 

ALP (U/L)

   

0.3106

 Mean (SD)

122.93(98.55)

101.36 (48.62)

95.81 (53.83)

 

PT (s)

   

0.0488

 Mean (SD)

11.92 (0.92)

12.01 (1.13)

12.55 (1.17)

 

Number of intrahepatic lesions (n)

   

0.0071

 ≤ 3

5 (17.24)

8 (40.00)

19 (55.88)

 

 > 3

24 (82.76)

12 (60.00)

15 (44.12)

 

Maximum diameter of intrahepatic tumor (cm)

   

0.4604

 ≤ 5

24 (82.76)

16 (80.00)

31 (91.18)

 

 > 5

5 (17.24)

4 (20.00)

3 (8.82)

 

Vascular invasion

   

0.4294

 Yes

2 (6.90)

0 (0.00)

1 (2.94)

 

 No

27 (93.10)

20 (100.00)

33 (97.06)

 

Extrahepatic metastases

   

0.0161

 Yes

7 (24.14)

6 (30.00)

1 (2.94)

 

 No

22 (75.86)

14 (70.00)

33 (97.06)

 

Time to recurrence after surgery

   

0.0140

 < 2

20 (68.97)

13 (65.00)

32 (94.12)

 

 ≥ 2

9 (31.03)

7 (35.00)

2 (5.88)

 

ALBI grade

   

0.7215

 1

12 (41.38)

11 (55.00)

19 (55.88)

 

 2

16 (55.17)

9 (45.00)

14 (41.18)

 

 3

1 (3.45)

0 (0.00)

1 (2.94)

 

ECGO PS

   

NA

 0

29 (100.00)

20 (100.00)

34 (100.00)

 

Child–Pugh

   

0.5352

 A

27 (93.10)

20 (100.00)

32 (97.06)

 

 B

2 (6.90)

0 (0.00)

1 (2.94)

 

Pre-operative AFP (ng/mL)

   

0.7429

 < 400

18 (62.07)

14 (70.00)

24 (70.59)

 

 ≥ 400

11 (37.93)

6 (30.00)

10 (29.41)

 

Microvascular invasion

   

0.9676

 M0

15 (51.72)

9 (45.00)

16 (47.06)

 

 M1

9 (31.03)

7 (35.00)

10 (29.41)

 

 M2

5 (17.24)

4 (20.00)

8 (23.53)

 

Tumor differentiation

   

0.6757

 Low

6 (20.69)

3 (15.00)

9 (26.47)

 

 Middle

22 (75.86)

15 (75.00)

24 (70.59)

 

 High

1 (3.45)

2 (10.00)

1 (2.94)

 

Satellite nodule

   

0.0398

 Yes

8 (27.59)

0 (0.00)

6 (17.65)

 

 No

21 (72.41)

20 (100.00)

28 (82.35)

 
  1. ECOG PS Eastern Cooperative Oncology Group performance status, AFP alpha-fetoprotein, ALBI albumin-bilirubin; Calculated using the following equation: linear predictor = (log10 bilirubin mmol/L × 0.66) + (albumin g/L × − 0.085). The continuous linear predictor was further categorized into three different grades for prognostic stratification purposes: grade 1 (less than − 2.60), grade 2 (between − 2.60 and − 1.39) and grade 3 (above − 1.39), ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, ALP Alkaline phosphatase, PT prothrombin time, TACE transarterial chemoembolization, HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us